Drugs targeting G-protein-coupled receptors (GPCRs) make up more than 25% of all prescribed medicines. The ability of GPCRs to form heteromers with unique signaling properties suggests an entirely new and unexplored pool of drug targets. However, current in vitro assays are ill equipped to detect heteromer-selective compounds. We have successfully adapted an approach, using fusion proteins of GPCRs and chimeric G proteins, to create an in vitro screening assay (in human embryonic kidney cells) in which only activated heteromers are detectable. Here we show that this assay can demonstrate heteromer-selective G-protein bias as well as measure transinhibition. Using this assay, we reveal that the d-opioid receptor agonist ADL5859, which is currently in clinical trials, has a 10-fold higher potency against d-opioid receptor homomers than d/m-opioid receptor heteromers (pEC 50 5 6.7 6 0.1 versus 5.8 6 0.2). The assay enables the screening of large compound libraries to identify heteromer-selective compounds that could then be used in vivo to determine the functional role of heteromers and develop potential therapeutic agents.
Introduction
G-protein-coupled receptors (GPCRs) form the largest protein family within the human genome. GPCRs are involved in many physiologic processes, including regulation of blood pressure and sensing of light and taste (Perez, 2003) . Moreover, these receptors play roles in many disease states, including cancer, hypertension, and drug addiction (AbdAlla et al., 2001; Koob and Volkow, 2010; Lappano and Maggiolini, 2011) . GPCRs are located on the cell membrane and are thus easily accessible to both endogenous and exogenous drug compounds. These attributes of GPCRs have contributed to the success of many of these drugs (Ma and Zemmel, 2002; Overington et al., 2006 ). Yet most GPCR drugs approved by the Food and Drug Administration target receptors that have been targeted previously (Ma and Zemmel, 2002; Overington et al., 2006; Swinney and Anthony, 2011) . Still, increased knowledge of GPCR pharmacology, including deorphanization, biased agonism, allosteric modulation, and heteromerization (Levoye et al., 2006; Conn et al., 2009; Whalen et al., 2011) , should provide new avenues for developing drugs against novel binding domains or targets.
Much attention has been given to the finding that GPCRs can interact with themselves (homomers) and with other GPCRs (heteromers) (Maurice et al., 2011) . Although monomeric GPCRs are the minimal signal unit (Whorton et al., 2007) , it has been reported that heteromers can have pharmacological properties distinct from those of the individual GPCRs of which they are made (Dalrymple et al., 2008; Ferre et al., 2010) . GPCR heteromers could thus represent a broad new range of accessible pharmaceutical targets (Dalrymple et al., 2008; Ferre et al., 2010) . However, the physiologic role of GPCR heteromers has been difficult to determine, in part because no pharmacological tools currently exist that selectively target heteromers, thus distinguishing their functional role from those of their homomers. Furthermore, coexpression of two GPCRs in vitro leads to the formation of both homomers and heteromers, which has hindered the identification of heteromer-selective binding and activity. Han et al. (2009) recently developed an approach to study homomer pharmacology. In this assay, a carboxy-terminally truncated dopamine D 2 receptor (D 2 R) was fused to a chimeric G protein (Conklin et al., 1993) to create a signaling-muted receptor. Activity was shown to be rescued, via functional complementation, through coexpression of a full-length wildtype (WT) (i.e., not fused) receptor, which itself is unable to signal without interacting with the chimeric G protein. The goal of the current study was to determine the feasibility of applying this complementation strategy to other family A GPCR homomers and, more importantly, to examine whether this method could be applied to selectively isolate heteromermediated G-protein signal transduction. Here we demonstrate that we have developed a robust, albeit artificial, screening assay that shows selective signaling from family A GPCR heteromers of diverse types. By extension, this assay should allow for the identification of heteromer-selective ligands for many family A GPCRs. Such heteromer-selective compounds could then be used in vivo to determine the roles of GPCR heteromers in both naïve and disease states.
Materials and Methods
Molecular Cloning of Receptor-Chimeric G-Protein Fusions. The chimeric G qi4 and G qs5 were kindly provided by Dr. E. Kostenis (University of Bonn, Bonn, Germany). The start codon of the G qi4 was removed by polymerase chain reaction (PCR) using the respective forward and reverse primers 59-TAATAGGATCCATAGGGTGCTGCCT-GAGCGAG-39 and 59-TACACGGGCCCTTAGAAGAGGCCACACT CCTTC-39 using G qi4 as a template. The PCR product was cloned into pcDNA3.1 after digestion with BamHI and ApaI, resulting in a "G qi4 -no start." DOR 373 -G qi4 and DOR 344 -G qi4 were then cloned using a standard T7 forward primer (59-TACGACTCACTATAGGGAGAC-39) and the reverse primers 59-TTATAGGATCCGGCGGCAGCGCCACC-39 and 59-ACATAGGATCCACTCCCGGGTTCTTGGCG-39 using FLAG-DOR as a template, followed by restriction of the PCR fragment and G qi4 -no start with NheI and BamHI. DOR 337 -G qi4 , DOR 333 -G qi4 , and DOR 323 -G qi4 were cloned using the T7 forward primer and the reverse primers 59-ATGGATCCGGGCGTGCGACAGAGCTGGCGG-39, 59-ATAAGGATCCGAGCTGGCCGGAAGCAGCGC-39, and 59-ATCGGA TCCCAGGAAGGCGTAGAGAACCG-39 using FLAG-DOR as a template, followed by restriction of the PCR fragment and DOR fl -G qi4 with HindIII and BamHI. DOR 333 -G qs5 was cloned by restriction of DOR 333 -G qi4 and G qs5 with AvrII and EcoRI. MOR 354 -G qi4 was cloned using the T7 forward primer and 59-CGAGATCTTGGGATGCAGAACTCTC-TAAAAC-39 as a reverse primer using FLAG-MOR as a template, followed by restriction of the PCR fragment with HindIII and BglII and DOR fl -G qi4 with HindIII and BamHI. D 1 R 350 -G qi4 was cloned using the respective forward and reverse primers 59-AGATGGATCCAAGTCTG-TAGCATCCTAAGAGG-39 and 59-GAACTGCTAGCCATGAAGACGAT-CATCGCC-39, followed by restriction of the PCR fragment and DOR 333 -G qi4 with NheI and BamHI. D 1 R 350 -G qs5 was cloned by restriction of D 1 R 350 -G qi4 and DOR-G qs5 with AvrII and EcoRI.
All constructs contained an N-terminal cleavable hemagglutinin signal peptide followed by a FLAG (DYKDDDDK) or HA (YPYDVP-DYA) peptide for enhanced cell surface expression and biochemical detection, respectively.
Calcium Mobilization. Human embryonic kidney (HEK-293) cells were maintained at 37°C humidified in 7% CO 2 /93% air atmosphere in Dulbecco's modified Eagle's medium supplemented with 10% (v/v) fetal calf serum. To measure calcium mobilization following activation of a G i -or G s -coupled receptor, we used chimeric G q proteins that contained either the last four or five N-terminal amino acids of the G i protein (G qi4 ) or G s protein (G qs5 ) (Kostenis, 2001) . Cells were transiently transfected using Lipofectamine 2000 (Invitrogen, Life Technologies, Grand Island, NY) with a single GPCR, a GPCR with a chimeric G protein, a GPCR-chimeric G-protein fusion, or a GPCR with a GPCR-G-protein chimera fusion Enzyme-Linked Immunosorbent Assay. The ELISA assay was performed as previously described (van Rijn et al., 2008) . In short, HEK-293 cells transiently expressing N-terminal FLAG-DOR receptors or truncated receptors in a 96-well plate (40,000 cells/well) were fixed for 30 minutes with 4% paraformaldehyde. Permeabilization, when applicable, was carried out using 0.5% NP40 in Tris-buffered saline (TBS) for 30 minutes. Cells were blocked for 4 hours using 0.1 M NaHCO 3 1% milk powder in TBS. Cells were incubated with primary antibodies (mouse Anti-FLAG-M2; Sigma, St. Louis, MO) overnight and secondary antibodies (goat anti-mouse HRP; Jackson ImmunoResearch Laboratories, West Grove, PA) for 2 hours. Cells were incubated with 3,39,5,59-tetramethylbenzidine (Sigma), and reactions were stopped with 0.5M H 2 SO 4 . The reaction mixture was measured at 450 nm. Between every step cells were washed at least three times with TBS. For the ELISA experiments, each data point was obtained at least in sextuplicate and the experiment was performed three times.
Fluorescent Imaging. HEK-293 cells transiently expressing Nterminal FLAG-DOR receptors or truncated receptors were incubated with monoclonal M1 anti-FLAG antibody (Sigma-Aldrich, St. Louis, MO) for 30 minutes to label surface receptors. Subsequently, cells were fixed with 3.7% formaldehyde in phosphate-buffered saline for 20 minutes at room temperature and permeabilized with 0.1% Triton X-100. Cells were then incubated with a subtype-selective fluorescent anti-mouse antibody directed against M1 (Alexa488 IgG2b; Invitrogen) for 30 minutes. After staining, cells were mounted in Vectashield mounting medium (Vector Laboratories, Burlingame, CA) and analyzed using a Zeiss LSM 510 META Axioplan 2 confocal microscope (Carl Zeiss Inc., Thornwood, NY).
Data Analysis. Dose-response curves for the calcium release assay were generated using Graphpad Prism (La Jolla, CA). The software automatically calculates 50% effective concentration values (pEC 50 ).
For one experiment, relative efficacy values (a) were calculated by setting the maximal effective response (E max ) at 100% for the response obtained for the agonist (morphine) in the absence of the antagonist (naltrindole).
Drugs and Reagents. 
Results

Creation of Truncated Receptor-Chimeric G qi -Protein Fusion Protein Attenuates Signal Transduction
Previous reports by Han et al. (2009) have shown that connecting a chimeric G qi5 protein to a carboxy-terminal-tailtruncated D 2 R produces a receptor that is unable to signal. We created fusion proteins with a chimeric G qi4 protein fused to the carboxy-terminal tail of either a full-length d-opioid receptor (DOR) or to DORs with increasingly truncated C-terminal tails ( Fig. 1A ; also see Methods). Shortening of the C-terminal tail attenuated signal transduction induced by the DOR-selective agonist SNC80 and the peptide agonist leuenkephalin ( Fig. 1B ; Table 1 ). Signal transduction was significantly attenuated when the receptor was truncated beyond the palmitoylation site (DOR 333 -G qi4 ) and was entirely abolished if the putative helix 8 (H8) was truncated as well (DOR 323 -G qi4 ) ( Fig. 1B ; Table 1 ). Fusion of the G protein to truncated DOR affected the distribution of the fusion protein compared with WT DOR; whereas nearly 100% of the WT DORs and full-length DOR 372 -G qi4 were expressed at the cell surface ( Fig. 1 , C-E), a significant fraction of fused truncated DORs were located intracellularly ( Table 2 ). To exclude that coexpressing DOR 333 -G qi4 with WT DOR causes increased surface expression of DOR 333 -G qi4 , which could potentially explain the functional complementation we observe, we performed an ELISA on the same pool of transfected cells. No increase in expression of the FLAG-DOR 333 -G qi4 was observed when it was coexpressed together with HA-DOR. In contrast, there was a decrease in the surface expression of FLAG-DOR 333 -G qi4 when coexpressed with HA-DOR, as compared with transfection with an empty expression vector (Fig. 2B) . The DOR 333 -G qi4 fusion protein was the shortest truncation of the DOR that could be rescued by complementation, as no G-protein signaling was induced by coexpression if the receptor was truncated directly after transmembrane domain 7 (TM7; DOR 323 -G qi4 ), eliminating the putative H8 (Fig. 2C) . We observed similar functional complementation of homomeric receptors of the m-opioid receptor (MOR), truncated after H8 and fused to the G qi4 -protein (MOR 354 -G qi4 ), when it was coexpressed with WT fulllength MOR (Fig. 2D ). These results demonstrate that this method of functional complementation can be used to study homomeric opioid receptors.
Next we examined whether this approach would allow the selective detection of G-protein signaling from heteromers. We found that the k-opioid receptor (KOR)-selective ligand U69,593 potently induced calcium release in cells in which the DOR 333 -G qi4 and KOR were expressed together ( Fig. 2E ; Table 2 ). Similar functional complementation was observed for the selective MOR agonist DAMGO in cells coexpressing DOR 333 -G qi4 and the MOR ( Fig. 2F ; Table 2 ). Importantly, none of the WT opioid receptors induced calcium release when they were expressed in HEK-293 cells in the absence of either DOR 333 -G qi4 or "nonfused" chimeric G qi4 proteins (Fig. 2G) . We also demonstrated that the functional complementation was bidirectional. Specifically, in cells coexpressing WT DOR with the MOR 354 -G qi4 fusion protein, the DOR agonist SNC80 induced calcium release ( Fig. 2H ; Table 2 ). Thus, we have demonstrated the ability to detect a signal exclusively from heteromers but not homomers in cells expressing a truncated, G-protein-fused opioid receptor and a full-length WT opioid receptor (Fig. 2I) .
Functional Complementation of G i -Coupled and G sCoupled Receptors
G i -Coupled Receptors. To examine whether functional complementation would occur between G i -coupled receptors belonging to different subclasses of family A GPCRs, we coexpressed the DOR 333 -G qi4 with either the D 2 R or the histamine H 4 receptor (H 4 R). Neither quinpirole nor histamine stimulation results in calcium release in HEK-293 cells expressing only DOR 333 -G qi4 or cells expressing D 2 R or H 4 R in the absence of the chimeric G qi4 protein (Fig. 3, A and B ). However, we were able to induce calcium release with the D 2 R-selective agonist quinpirole or the H 4 R-selective agonist histamine when DOR 333 -G qi4 was coexpressed with D 2 R or H 4 R, respectively (Fig. 3, A and B) , suggesting that functional complementation occurs between different G i -coupled receptors.
G s -Coupled Rreceptors. Next, we truncated the dopamine D 1 receptor (D 1 R) after H8 and fused it to the chimeric G qs5 protein (D 1 R 350 -G qs5 ) to determine if we could observe functional complementation for receptors that preferentially signal through G s proteins. We observed that the D 1 Rselective agonist SKF81297 was unable to induce calcium release in cells expressing only D 1 R 350 -G qs5 (Fig. 4A) , but we were able to restore signal transduction coexpressing WT D 1 R (Fig. 4A) , suggesting that this technique of functional complementation can be employed to study both G i -and G scoupled receptors.
Functional Complementation between G s -and G iCoupled Receptors. We next investigated whether we could observe functional complementation between D 1 R and DOR using cells coexpressing D 1 R 350 -G qs5 and DOR. However, we were unable to observe any calcium release by SKF81297 or SNC80 in these cells ( Fig. 4B; Table 3 ). Interestingly, SKF81297 and SNC80 did induce calcium release in cells expressing D 1 R 350 -G qi4 and DOR ( Fig. 4C ; Table 3 ). We also determined that SKF81297 did not induce calcium release in cells expressing D 1 R 350 -G qi4 alone (Fig. 4C) . To further study this observation, we fused truncated DOR 333 to the G qs5 protein. DORs preferentially signal through G i proteins; hence we did not expect DOR 333 -G qs5 to signal. Indeed, no calcium release was observed when SNC80 was applied to cells expressing DOR 333 -G qs5 ( Fig. 4D; Table 3 ). Yet similar to the calcium release induced in cells coexpressing D 1 R 350 -G qi4 and DOR, SKF81297 induced calcium release in cells coexpressing DOR 333 -G qi4 and D 1 R ( Fig. 4E ; Table 3 ), suggesting that heteromers of DOR and D 1 R preferentially couple only to G i proteins. We also observed functional complementation when coexpressing DOR 333 -G qs5 and the histamine H 2 receptor (H 2 R), which preferentially couples to G s proteins (Hill et al., 1997) , using the H 2 R-selective agonist dimaprit ( Fig. 4F ; Table 3 ), suggesting that the lack of G qsmediated signal transduction observed when coexpressing DOR and D 1 R is unique to this combination. However, calcium release occurred only when the H 2 R-DOR 333 -G qs5 complex was bound by dimaprit, but not when bound by the SNC80 8.4 6 0.2 8.3 6 0.3 6.4 6 0.2*** 6.8 6 0.3*** 7.0 6 0.1*** ,5 Leu-enkephalin 7.9 6 0.2 8.1 6 0.1 7.4 6 0.2 7.3 6 0.2 7.6 6 0.2 ,5 ***P , 0.001 vs. DOR + G qi4 . pEC50=-Log(50%effective concentration). Novel HTS Assay for Heteromer-Selective Drugs DOR-selective agonist SNC80 ( Fig. 4F ; Table 3 ). We also observed calcium release with dimaprit when DOR 333 -G qi4 was coexpressed with H 2 R ( Fig. 4G ; Table 3 ). SNC80 also induced a calcium response in cells expressing DOR 333 -G qi4 with H 2 R, thus suggesting that the DOR-H 2 R heteromer may be able to signal through either G s or G i proteins, and suggesting that this was dependent on the ligand. We also observed functional complementation between two G s -coupled receptors using cells coexpressing D 1 R 350 -G qs5 and H 2 R (Fig. 4H) . We next determined whether we could detect a heteromer-selective signal not only in a 96-well but also in a 384-well format. Using cells expressing the D 1 R 350 -G qs5 -H 2 R heteromer, we demonstrated that the assay is functional in a 384-well format as well (Fig. 4H) . Transinhibition. Knockout, knockdown, or pharmacological inhibition of DORs has been reported to attenuate morphine tolerance, place preference, and dependence (Miyamoto et al., 1993; Zhu et al., 1999; Shippenberg et al., 2009 ). Some of these effects have been attributed to DOR-MOR heteromers (Rozenfeld et al., 2007) . Devi and coworkers have shown that both DOR agonists and antagonists act as positive modulators for morphine activity in cells and tissues coexpressing DOR and MOR (Gomes et al., 2004; Gupta et al., 2010) . We next examined whether the positive modulation was due to allosteric enhancement of morphine's activity at the MOR-DOR heteromer upon DOR ligand binding. At 10 nM, naltrindole does not compete with morphine in cells expressing MOR alone (pEC 50 , 8.1 6 0.1 versus 8.0 6 0.1; a, 100 6 0.1 versus 106 6 3; n 5 3) (Fig. 5A) . Nevertheless, in cells coexpressing DOR 333 -G qi4 with MOR, we found that naltrindole significantly (P 5 0.004) attenuated morphine signaling (pEC 50 , 7.0 6 0.2 versus 7.0 6 0.1; a, 100 6 0.1 versus 60 6 4; n 5 3) (Fig. 5B) . We determined that morphine was unable to induce calcium release in cells expressing only DOR 333 -G qi4 (Fig. 5B) . These assays were performed with the same transfected cells to control for expression levels. These data suggest that the increased activity of morphine produced by naltrindole in cells or tissues expressing both MOR and DOR is not due to increased activity of morphine at the MOR-DOR heteromer via a positive allosterism produced by naltrindole. On the contrary, it appears that naltrindole acts as a negative allosteric modulator for the effects of morphine on the MOR-DOR heteromer.
Screening for Homomer-and Heteromer-Selective Compounds
We envision that the key use of this heteromer assay will be to identify compounds that are selective for a GPCR heteromer. To validate the heteromer assay for this purpose, we tested four DOR-selective compounds for their activity on DOR homomers (DOR 333 -G qi4 1 DOR), MOR homomers (MOR 354 -G qi4 1 MOR), and DOR-MOR heteromers (DOR 333 -G qi4 1 MOR; MOR 354 -G qi4 1 DOR). The set included deltorphin II, an amphibian-derived peptide (Kreil et al., 1989) ; a DOR agonist currently in phase 2 clinical trials, ADL5859 (Le Bourdonnec et al., 2008) ; as well as two agonists, SNC80 and ARM1000390, that differ in their ability to internalize the DOR (Pradhan et al., 2009) . Deltorphin II displayed similar activity on the DOR homomer and the DOR-MOR heteromers ( Fig. 6A; Table 4 ). However, the other three compounds, all of which had been designed to exhibit a high degree of DOR selectivity (Calderon et al., 1994) , have a higher potency against DOR homomers than DOR-MOR heteromers or MOR homomers (Table 4 ). In particular, ADL5859 is significantly more potent at DOR homomers than at DOR-MOR heteromers ( Fig. 6B ; Table 4 ).
Discussion
Here we show that the ability of GPCRs truncated after the putative H8 and fused to chimeric G q proteins to induce calcium release is severely attenuated (Fig. 2A) or abolished (Figs. 2D and 4A ). More importantly, we demonstrate functional complementation in several diverse heteromeric complexes when these fusion proteins are coexpressed with a WT receptor. When used with the proper controls, this assay can be used to identify molecules with selective activity at heteromeric GPCRs. Specifically, for any heteromeric target of interest, for example, DOR-MOR, one would screen three receptor combinations: DOR 333 -G qi4 1 DOR, MOR 354 -G qi4 1 MOR, and DOR 333 -G qi4 1 MOR. A fourth combination, i.e., MOR 354 -G qi4 1 DOR, could be tested as well (Fig. 6) . Ligands that show increased activity in the heteromeric cell line compared with the homomer-only-expressing cells would be heteromer-selective. Conversely, ligands that are more active in the homomer-than the heteromer-expressing cells, such as ADL5859 (Fig. 6B) , would be homomer-selective. Furthermore, here we show that this strategy allows for the detection of heteromer-specific pharmacology, including different G-protein preference (Fig. 4 , B-E) and negative allosteric modulation (Fig. 5, A and B) . Our finding that heteromers between DOR and D 1 R show a strong preference for engaging G i over G s proteins is also interesting, as a similar switch in G-protein coupling preference by heteromerization has recently been described for the serotonin 5-HT 2A and metabotropic glutamate 2 receptor (Fribourg et al., 2011) , which was suggested to be caused by crosstalk between the two receptors through a heteromer interface (Bruno et al., 2009) .
Because of the artificial nature of the heteromer assay, which allows for high expression levels, it could be proposed that functional complementation is achieved by the WT receptors being in close proximity to the chimeric G-proteinfused receptors and directly interacting with only the Novel HTS Assay for Heteromer-Selective Drugs chimeric G protein without engaging in heterodimer formation. Yet our finding that the D 1 R does not interact with G qs proteins when fused to the DOR suggests that this is not the case.
It is important to note that the robustness of the assay is derived from expressing the chimeric G-protein-fused receptors and WT receptors at levels that are not necessarily natural. Similar to other in vitro assays that study GPCR heteromers, such as resonance energy transfer techniques and coimmunoprecipitation, a heteromer-derived signal in this assay is no guarantee of the heteromer's existence in vivo. However, in contrast to the other methods, the heteromer assay described here will ultimately provide us with a tool that allows the study of heteromer function in vivo.
Although several assays exist to probe for GPCR heteromer formation, few high-throughput screening assays are available that allow for the identification of heteromer-selective compounds. One approach has involved fusing a G protein to a receptor that is unable to bind ligands due to a point mutation in the binding domain, and coexpressing this fusion protein with a separate receptor that is unable to be activated due to a point mutation in the signaling domain of the receptor, thus gaining functional complementation through mandatory transactivation (Milligan et al., 2007) . Such an approach was recently used in an elegant study to show that the luteinizing hormone receptor forms dimers in vivo (Rivero-Muller et al., 2010) . In this case, neither GPCR is a WT receptor, as both carry different point mutations and must be expressed as fusion proteins, whereas the assay we describe requires the creation of only one fusion protein. Dimerix Bioscience (Bundoora, Australia), with GPCR-HIT, and DiscoveRx (Fremont, CA), with PathHunter, also have proprietary dimer assays, which use a tagged GPCR and b-arrestin fusion proteins that can only be activated by the tagged GPCR. The tagged GPCR thus allows for the detection of the formation of dimers that signal through b-arrestin by functional transcomplementation. Importantly, whereas our G-protein-based heteromer assay eliminates both homomer signals (Fig. 2I) , the aforementioned b-arrestin-based assays only remove one of the two homomer signals. Still, when used in parallel, these assays could identify ligand bias for G protein versus b-arrestin for any heteromeric-specific ligand.
It is worth mentioning that not every GPCR interacts well with the chimeric G proteins (Coward et al., 1999) . Also, the current setup does not allow for the detection of heteromers containing G q -coupled receptor, as their homomers would already induce a signal on their own. Nevertheless, several options exist for expanding this assay to include the study of G q -coupled GPCRs. Similar to G qs and G qi chimeric proteins, G iq (Grisshammer and Hermans, 2001 ) and G sq (Hsu and Luo, 2007) chimeras have been produced. Fusing a G q -coupled receptor to such a chimera would allow the selective activation of heteromers consisting of two G q -coupled GPCRs (Fig. 7A) . Selective activation of a heteromer consisting of a G q -coupled GPCR and a G i -coupled GPCR could be achieved by fusing one of the receptors to the pertussis-toxininsensitive G iq protein and measuring cAMP inhibition in the presence of pertussis toxin (Fig. 7B) .
As the physiologic role of specific heteromers becomes more apparent, it may become evident that heteromer activation can have both desirable and undesirable effects. Therefore, either prevention or disruption of heteromer formation could also be a therapeutic strategy. To this end, an increasing effort has been made to develop protein-protein interaction inhibitors (Mullard, 2012) . Since this assay detects an exclusively heteromer-derived signal, it allows for the study of the receptor interface via point mutations at the predicted heteromer interface. Moreover, small peptide (TM-like) fragments could be developed with the potential of disrupting the interface (He et al., 2011) . However, it may also be possible to disrupt heteromers with ligands that change the conformation of the GPCR in a way that is unfavorable to sustaining or inducing heteromer formation (or that favors homomer formation).
Recently, the crystal structures of the opioid receptors have been resolved. Although the DOR was not crystallized in a dimer lattice , several GPCRs have been crystallized as dimers (Fotiadis et al., 2003; Wu et al., 2010) , including the MOR and KOR (Wu et al., 2012) . Interestingly the crystal structure of the MOR revealed the potential of a tight interaction between TM5 and TM6 of the MOR, a region highly conserved between MOR and DOR. In several instances, H8, a region that has been known to be important for receptor signal transduction (Tetsuka et al., 2004; Feierler et al., 2011) , is involved in the dimer interface (Salom et al., 2006; Manglik et al., 2012; Wu et al., 2012) . In our experiments, it appears that H8 needs to remain intact for functional complementation to occur, which would be in line with those previous findings. The crystal structures should allow for improved computer models for predicting how the binding of ligands to one pharmacophore might affect the homomer/heteromer interface and, allosterically, the binding pocket of the second receptor (Maurice et al., 2011) . Indeed, one possible explanation for the observed inhibition of morphine-induced calcium release from the DOR-MOR heteromer with the DOR antagonist naltrindole could be decreased DOR-MOR heteromer formation.
In conclusion, here we describe an in vitro assay that provides a robust method enabling the study of GPCR heteromer pharmacology at diverse targets without the confounding effects of homomeric signaling. When used appropriately, this assay could lead to the discovery of new heteromer-selective compounds. This in turn will facilitate research on the role of heteromers in human (patho-) physiology. Novel HTS Assay for Heteromer-Selective Drugs
